Krishna Vaddi, CEO at Prelude Therapeutics Inc (PRLD), bought 1,900 shares at $5.01 ($10K) on 2023-05-24, disclosed to the SEC on 2023-05-26.
Open-market purchase of $10k PRLD by CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.01 | 1,000 | $5K | 51.2% |
| 2 | $5.31 | 900 | $5K | 48.8% |
| Total | $5.15 avg | 1,900 | $10K | 100% |
| Filing → |
| PRLD | BUY | 2025-03-18 | $29K | — | Filing → |
| PRLD | BUY | 2025-03-14 | $70K | — | Filing → |
| PRLD | BUY | 2025-01-03 | $6K | — | Filing → |